Enanta Pharmaceuticals, Inc.
ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identifyā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$12.95
Price+2.78%
$0.35
1Y
Price
Market Cap
$376.565m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-49.9%
EBITDA Margin-76.3%
Net Profit Margin-41.8%
Free Cash Flow Margin-49.9%
EBITDA Margin-76.3%
Net Profit Margin-41.8%
Free Cash Flow MarginRevenue
$69.213m
+6.0%
1y CAGR-4.0%
3y CAGR-5.0%
5y CAGREarnings
-$61.984m
+24.3%
1y CAGR+22.3%
3y CAGR+14.3%
5y CAGREPS
-$2.74
+28.7%
1y CAGR+24.2%
3y CAGR+16.2%
5y CAGRBook Value
$116.587m
$314.704m
Assets$198.117m
Liabilities$186.617m
DebtDebt to Assets
59.3%
-4x
Debt to EBITDAFree Cash Flow
-$9.609m
+70.1%
1y CAGR+50.2%
3y CAGR+30.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company